dc.contributor.author |
Wijekoon, S |
|
dc.contributor.author |
Wijekoon, CN |
|
dc.date.accessioned |
2017-10-04T09:37:50Z |
|
dc.date.available |
2017-10-04T09:37:50Z |
|
dc.date.issued |
2016 |
|
dc.identifier.citation |
S. Wijekoon, C.N. Wijekoon, (2016) "Audit of clopidogrel use in a medical clinic in a tertiary care hospital in Sri Lanka", Journal of the Ceylon College of Physicians, Vol. 47 Iss: 2, pp.82-8586 |
en_US, si_LK |
dc.identifier.uri |
http://dr.lib.sjp.ac.lk/handle/123456789/5609 |
|
dc.description |
Page 1. 82 Journal of the Ceylon College of Physicians Wijekoon S, Wijekoon CN Wijekoon S1,
Wijekoon CN1 Journal of the Ceylon College of Physicians, 2016, 47, 82-85 Paper Audit of
clopidogrel use in a medical clinic in a tertiary care hospital in Sri Lanka 1 Faculty of Medical
Sciences, University of Sri Jayewardenepura. Corresponding author: SW E-mail:
sanjeewa_wijekoon@sjp.ac.lk Data about prescription pattern of clopidogrel in the local setting
will be valuable to formulate a plan to minimize unnecessary use of clopidogrel. ... |
en_US, si_LK |
dc.description.abstract |
Introduction
Clopidogrel is a widely used anti-platelet agent.
The active metabolite of clopidogrel blocks the
interaction between adenosine diphosphate and P2Y12
receptor and prevents ADP mediated activation of
aglycoprotein GPIIb/IIIa complex and thereby inhibits
platelet aggregation. It is an irreversible inhibition.
Clopidogrel is used as monotherapy or in combination
with aspirin in management of cardiovascular
diseases (CVD); namely coronary artery disease (CAD),
ischaemic stroke and transient ischaemic attack (TIA).
Several large multicentre clinical trials have shown the
benefits of clopidogrel in cardiovascular diseases.1,2
American Heart Association (AHA), American College
of Cardiology (ACC) and American Stroke Association
(ASA) guidelines3,4,5,6,7,8,9 have given clear evidene based
recommendations for clopidogrel use.
The guidelines strongly recommend to start dual
antiplatelet therapy (DAPT) with clopidogrel and aspirin
after an acute coronary syndrome (ACS). Maximum
recommended duration of DAPT after an ACS managed
without percutaneous intervention is 12 months. After
a minor stroke/TIA, DAPT with clopidogrel and aspirin
might be considered within 24 hours and continued for
21 days; however the strength of this recommendation is
weak. Clopidogrel monotherapy is generally recommended
for secondary prevention of CVD only if there is
aspirin intolerance. In primary prevention of CVD
clopidogrel is not recommended. A summary of these
recommendations is shown in table 1.
However clopidogrel use is associated with an
increased risk of major bleeding including haemorhagic
stroke and gastro-intestinal bleeding. This risk is further
increased when it is combined with aspirin. Specially, long
term DAPT confers a significantly higher risk of
haemorrhagic complications.10,11,12,13 Therefore it is
extremely important to ensure that clopidogrel is
prescribed appropriately for recommended indications
and it is not used beyond the recommended duration Data about prescription pattern of clopidogrel in
the local setting will be valuable to formulate a plan to
minimize unnecessary use of clopidogrel. However a
literature survey did not reveal any previous publications
about clopidogrel use in Sri Lanka. |
en_US, si_LK |
dc.language.iso |
en_US |
en_US, si_LK |
dc.publisher |
Ceylon College of Physicians |
en_US, si_LK |
dc.subject |
stroke |
en_US, si_LK |
dc.subject |
knowledge |
en_US, si_LK |
dc.subject |
developing country |
en_US, si_LK |
dc.subject |
Sri Lanka |
en_US, si_LK |
dc.subject |
awareness |
en_US, si_LK |
dc.title |
Audit of clopidogrel use in a medical clinic in a tertiary care hospital in Sri Lanka |
en_US, si_LK |
dc.type |
Article |
en_US, si_LK |